Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the achilles heel of targeted therapy

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 203-213

  Budha, N R ^a   Frymoyer, A ^b   Smelick, G S ^a   Jin, J Y ^a   Yago, M R ^b   Dresser, M J ^a   Holden, S N ^a   Benet, L Z ^b   Ware, J A ^a  

^a GENENTECH INC   (United States)

^b San Francisco   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTINEOPLASTIC AGENT; AXITINIB; CALCIUM CARBONATE; CALCIUM HYDROXIDE; CIMETIDINE; CRIZOTINIB; DASATINIB; ERLOTINIB; ESOMEPRAZOLE; EVEROLIMUS; FAMOTIDINE; GEFITINIB; IMATINIB; LANSOPRAZOLE; LAPATINIB; NILOTINIB; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PAZOPANIB; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; VISMODEGIB;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH PH; TREATMENT INDICATION;

ANTICARCINOGENIC AGENTS; DRUG INTERACTIONS; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; NEOPLASMS; PROTON PUMP INHIBITORS; SOLUBILITY;

EID: 84864127874     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.73     Document Type: Article

References (66)

1. Hay, M., Rosenthal, J., Thomas, D. & Craighead, J. BIO/BioMedTracker Clinical Trial Success Rates Study (2011). Presentation at Biotechnology Industry Organization (BIO) CEO & Investor Conference-15 February 2011. 〈http://insidebioia.files.wordpress.com/2011/02/bio-ceo-biomedtracker-bio- studyhandout-2-15-20111.pdf〉. Accessed 18 April 2011.
2. Undevia, S.D., Gomez-Abuin, G. & Ratain, M.J. Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 5, 447-458 (2005). (Pubitemid 40791487)
3. S parreboom, A. & Verweij, J. Advances in cancer therapeutics. Clin. Pharmacol. Ther. 85, 113-117 (2009).
4. Wienkers, L.C. & Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4, 825-833 (2005). (Pubitemid 41553963)
5. G iacomini, K.M. et al.; International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
6. US Food and Drug Administration. Dasatinib (Sprycel) prescribing information (2010).
7. US Food and Drug Administration. Gefitinib (Iressa) prescribing information (2004).
8. US Food and Drug Administration. Erloitinib (Tarceva) prescribing information (2010).
9. US Food and Drug Administration. Nilotinib (Tasigna) prescribing information (2010).
10. S melick, G.S.et al. Prevalence of acid-reducing agents in cancer (CA) populations: an epidemiological perspective to predict drug-drug interaction (DDI) potential of orally administered pH-dependent cancer therapeutics S110. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbor, MD, 12-17 March 2012.
11. G uevremont, C., Alasker, A. & Karakiewicz, P.I. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr. Opin. Support. Palliat. Care 3, 170-179 (2009).
12. Ferté, C. et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur. J. Cancer 47, 2249-2255 (2011).
13. US Food and Drug Administration. Dasatinib (Sprycel)-Summary Basis of Approval (2006).
14. US Food and Drug Administration. Dasatinib (Sprycel)-Chemistry Review of New Drug Application (2006).
15. Benet, L.Z., Broccatelli, F. & Oprea, T.I. BDDCS applied to over 900 drugs. AAPS J. 13, 519-547 (2011).
16. Dai, G., Pfister, M., Blackwood-Chirchir, A. & Roy, A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J. Clin. Pharmacol. 48, 1254-1269 (2008).
17. Eley, T. et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J. Clin. Pharmacol. 49, 700-709 (2009).
18. Clinical Study Report. The Effect of Omeprazole on the Pharmacokinetics of Dasatinib (BMS-354825) in Healthy Subjects 〈clinicalstudyresults. org〉 (2009).
19. US Food and Drug Administration. Gefitinib (Iressa)-Clinical Pharmacology and Biopharmaceutics Review (2003).
20. Bergman, E. et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int. J. Pharm. 341, 134-142 (2007). (Pubitemid 47096678)
21. European Medicines Agency. Gefitinib (Iressa)-Assessment Report (2009).
22. US Food and Drug Administration. Imatinib (Gleevec) prescribing information (2009).
23. Egorin, M.J. et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br. J. Clin. Pharmacol. 68, 370-374 (2009).
24. S parano, B.A. et al. Effect of antacid on imatinib absorption. Cancer Chemother. Pharmacol. 63, 525-528 (2009).
25. European Medicines Agency. Lapatinib (Tykerb)-Summary of Product Characteristics (2010).
26. US Food and Drug Administration. Lapatinib (Tykerb) prescribing information (2010).
27. G laxo Clinical Trial Report. An Open-Label, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects with Metastatic ErbB2 Positive Breast Cancer (2010). Published report 〈http://download.gsk-clinicalstudyregister.com/ files/9ed5ea0d-8365-439f-98e4-96119b2189e9〉. Accessed 9 March 2012.
28. US Food and Drug Administration. Nilotinib (Tasigna)-Clinical Pharmacology and Biopharmaceutics Review (2007).
29. Yin, O.Q. et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J. Clin. Pharmacol. 50, 960-967 (2010).
30. US Food and Drug Administration. Pazopanib (Votrient)-Chemistry (CMC) Review (2009).
31. US Food and Drug Administration. Pazopanib (Votrient) prescribing information (2010).
32. US Food and Drug Administration. Pazopanib (Votrient)-Clinical Pharmacology and Biopharmaceutics Review (2009).
33. European Medicines Agency. Sorafenib-EPAR Scientific Discussion (2010).
34. US Food and Drug Administration. Sorafenib (Nexavar)-Clinical Pharmacology and Biopharmaceutics Review (2005).
35. US Food and Drug Administration. Sorafenib (Nexavar) prescribing information (2010).
36. Lind, J.S. et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 3078-3087 (2010).
37. US Food and Drug Administration. Sunitinib (Sutent) prescribing information (2010).
38. US Food and Drug Administration. Sunitinib (Sutent)-Clinical Pharmacology and Biopharmaceutics Review (2006).
39. US Food and Drug Administration. Everolimus (Afinitor)-Clinical Pharmacology and Biopharmaceutics Review (2009).
40. US Food and Drug Administration. Everolimus (Afinitor) prescribing information (2010).
41. US Food and Drug Administration. Vandetanib (Zactima) prescribing information (2011).
42. US Food and Drug Administration. Vandetanib (Zactima)-Clinical Pharmacology and Biopharmaceutics Review (2010).
43. US Food and Drug Administration. Crizotinib (Xalkori) prescribing information (2011).
44. US Food and Drug Administration. Crizotinib (Xalkori)-Clinical Pharmacology and Biopharmaceutics Review (2011).
45. US Food and Drug Administration. Vemurafenib (Zelboraf)-Clinical Pharmacology and Biopharmaceutics Review (2011).
46. US Food and Drug Administration. Vismodegib (Erivedge) prescribing information (2012).
47. G raham, R.A. et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab. Dispos. 39, 1460-1467 (2011).
48. G raham, R.A. et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin. Cancer Res. 17, 2512-2520 (2011).
49. US Food and Drug Administration. Vismodegib (Erivedge)-Clinical Pharmacology and Biopharmaceutics Review (2012).
50. US Food and Drug Administration. Axitinib (Inlyta)-Clinical Pharmacology and Biopharmaceutics Review (2012).
51. US Food and Drug Administration. Axitinib (Inlyta) prescribing information (2012).
52. G olub, A.L., Frost, R.W., Betlach, C.J. & Gonzalez, M.A. Physiologic considerations in drug absorption from the gastrointestinal tract. J. Allergy Clin. Immunol. 78, 689-694 (1986). (Pubitemid 17170582)
53. S ugano, K. Computational oral absorption simulation of free base drugs. Int. J. Pharm. 398, 73-82 (2010).
54. S ugano, K. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. Int. J. Pharm. 405, 79-89 (2011).
55. Hirtz, J. The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br. J. Clin. Pharmacol. 19 (suppl. 2), 77S-83S (1985). (Pubitemid 16193625)
56. Higuchi, W.I., Ho, N.F.H. & Merkle, H.P. Design of oral drug delivery systems-past, present, and future. Drug Dev. Ind. Pharm. 9, 13 (1983).
57. S ugano, K. Introduction to computational oral absorption simulation. Expert Opin. Drug Metab. Toxicol. 5, 259-293 (2009).
58. Benet, L.Z. & Larregieu, C.A. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin. Pharmacol. Ther. 88, 405-407 (2010).
59. Wu, C.Y. & Benet, L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005). (Pubitemid 40558141)
60. S im, S.C. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006). (Pubitemid 43069582)
61. Klotz, U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther. 44, 297-302 (2006). (Pubitemid 44043771)
62. Custodio, J.M., Wu, C.Y. & Benet, L.Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 60, 717-733 (2008).
63. US Food and Drug Administration. Erlotinib (Tarceva)-Clinical Pharmacology and Biopharmaceutics Review (2004).
64. US Food and Drug Administration. Imatinib (Gleevec)-Clinical Pharmacology and Biopharmaceutics Review (2002).
65. S zakács, Z., Béni, S., Varga, Z., Orfi, L., Kéri, G. & Noszál, B. Acid-base profiling of imatinib (gleevec) and its fragments. J. Med. Chem. 48, 249-255 (2005). (Pubitemid 40105263)
66. US Food and Drug Administration. Lapatinib (Tykerb)-Clinical Pharmacology and Biopharmaceutics Review (2007).